Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Other Non-Current Assets (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Other Non-Current Assets data on record, last reported at $871000.0 in Q3 2025.

  • For Q3 2025, Other Non-Current Assets fell 41.93% year-over-year to $871000.0; the TTM value through Sep 2025 reached $871000.0, down 41.93%, while the annual FY2024 figure was $879000.0, 30.51% down from the prior year.
  • Other Non-Current Assets reached $871000.0 in Q3 2025 per SGMO's latest filing, down from $1.5 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $17.4 million in Q2 2023 and bottomed at $871000.0 in Q3 2025.
  • Average Other Non-Current Assets over 5 years is $8.9 million, with a median of $14.1 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: tumbled 90.21% in 2022, then soared 982.8% in 2023.
  • A 5-year view of Other Non-Current Assets shows it stood at $15.3 million in 2021, then crashed by 90.21% to $1.5 million in 2022, then decreased by 15.67% to $1.3 million in 2023, then crashed by 30.51% to $879000.0 in 2024, then dropped by 0.91% to $871000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $871000.0 in Q3 2025, $1.5 million in Q2 2025, and $882000.0 in Q1 2025.